United Health Products, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
OQB
United Health Products reports no revenue for the period, continues to address FDA regulatory concerns, and highlights substantial doubt about its going concern status while securing financing.
OQB
United Health Products reports zero revenue for Q1 2026 as it continues to focus on FDA Premarket Approval for its CelluSTAT hemostatic gauze.
OQB
United Health Products, Inc. reported a significant increase in net loss for the nine months ended September 30, 2025, alongside ongoing FDA regulatory challenges for its CelluSTAT product and a 'going concern' warning.
OQB
United Health Products, Inc. reported continued net losses and significant regulatory challenges for its CelluSTAT hemostatic gauze, including an FDA Warning Letter and disapproval of a key clinical trial application.
OQB
United Health Products reports no revenue for Q1 2025 as it continues to pursue FDA Premarket Approval for its CelluSTAT hemostatic gauze.
OQB
United Health Products reports a net loss for Q3 2024, with no revenue, as the company continues to focus on obtaining FDA approval for its CelluSTAT product.
OQB
United Health Products reported a net loss for the second quarter of 2024 and is addressing deficiencies in its FDA application for its hemostatic gauze product.
OQB
United Health Products reports a net loss of $451,938 for the first quarter of 2024, as the company focuses on obtaining regulatory approval for its hemostatic gauze product.